Trials / Recruiting
RecruitingNCT06044077
A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
A Randomized, Blinded, Parallel Controlled Phase 3 Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People Aged 2 Years and Above
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,920 (estimated)
- Sponsor
- Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Accepted
Summary
This study is a randomized, blinded, parallel controlled phase 3 clinical trial to evaluate the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and above.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 23-valent pneumococcal polysaccharide vaccine | 23-valent pneumococcal polysaccharide vaccine from Aimei Vacin BioPharm (Zhejiang) Co., Ltd. |
| BIOLOGICAL | control pneumococcal polysaccharide vaccine | 23-valent pneumococcal polysaccharide vaccine from Merck Sharp \& Dohme Corp |
Timeline
- Start date
- 2023-09-08
- Primary completion
- 2024-03-08
- Completion
- 2029-07-31
- First posted
- 2023-09-21
- Last updated
- 2023-09-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06044077. Inclusion in this directory is not an endorsement.